Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TALAZOPARIB Cause Wrong technique in product usage process? 7 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Wrong technique in product usage process have been filed in association with TALAZOPARIB (Talzenna). This represents 0.5% of all adverse event reports for TALAZOPARIB.

7
Reports of Wrong technique in product usage process with TALAZOPARIB
0.5%
of all TALAZOPARIB reports
0
Deaths
2
Hospitalizations

How Dangerous Is Wrong technique in product usage process From TALAZOPARIB?

Of the 7 reports, 2 (28.6%) required hospitalization.

Is Wrong technique in product usage process Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TALAZOPARIB. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does TALAZOPARIB Cause?

Anaemia (219) Neoplasm progression (169) Death (142) Off label use (78) Thrombocytopenia (78) Fatigue (77) Platelet count decreased (68) Haemoglobin decreased (65) Febrile neutropenia (60) Pancytopenia (60)

What Other Drugs Cause Wrong technique in product usage process?

EVOLOCUMAB (21,664) ALBUTEROL (17,114) ADALIMUMAB (11,766) PEGFILGRASTIM (10,217) ETANERCEPT (9,835) ERENUMAB-AOOE (9,359) SACUBITRIL\VALSARTAN (8,022) LEUPROLIDE (5,062) FENTANYL (2,812) SEMAGLUTIDE (2,538)

Which TALAZOPARIB Alternatives Have Lower Wrong technique in product usage process Risk?

TALAZOPARIB vs TALC TALAZOPARIB vs TALIGLUCERASE ALFA TALAZOPARIB vs TALIMOGENE LAHERPAREPVEC TALAZOPARIB vs TALQUETAMAB TALAZOPARIB vs TALQUETAMAB-TGVS

Related Pages

TALAZOPARIB Full Profile All Wrong technique in product usage process Reports All Drugs Causing Wrong technique in product usage process TALAZOPARIB Demographics